^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    VarMap™ Pan-Cancer NGS Panel

    Company:
    NuProbe
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    7ms
    Targeted sequencing of Circulating Tumor Cells captured by Parsortix® System enables low frequency variant analysis with NuProbe VarMap™ Pan-Cancer NGS Panel (EACR 2024)
    This study identified potentially actionable biomarkers in CTCs enriched using the Parsortix system, from cancer patient samples. Analysing the genetic profile of both CTCs and cfDNA, concomitantly, has the potential to better guide personalised treatment selection and monitoring of therapeutic response outcomes.
    Circulating tumor cells • Next-generation sequencing • Pan tumor • Tumor cell
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    Parsortix Liquid Biopsy • VarMap™ Pan-Cancer NGS Panel